[HTML][HTML] Therapeutic challenge for immunotherapy targeting cold colorectal cancer: A narrative review
SX Ma, L Li, H Cai, TK Guo… - World Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Cold colorectal tumors are not likely to trigger a robust immune response and tend to
suppress the immune response. There may be three reasons. First, the complex tumor …
suppress the immune response. There may be three reasons. First, the complex tumor …
Understanding the role of DNA methylation in colorectal cancer: Mechanisms, detection, and clinical significance
N Zhao, C Lai, Y Wang, S Dai, H Gu - … et Biophysica Acta (BBA)-Reviews on …, 2024 - Elsevier
Colorectal cancer (CRC) is one of the deadliest malignancies worldwide, ranking third in
incidence and second in mortality. Remarkably, early stage localized CRC has a 5-year …
incidence and second in mortality. Remarkably, early stage localized CRC has a 5-year …
[HTML][HTML] IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma
C Liu, W Zhang, X Zhou, L Liu - Frontiers in Immunology, 2022 - frontiersin.org
Backgrounds IMPDH1, a rate-limiting enzyme in de novos synthesis of guanine nucleotides,
plays an essential role in the growth and progression of certain tumors. However, there is …
plays an essential role in the growth and progression of certain tumors. However, there is …
Combining Immunotherapy and Radiation therapy in Gastrointestinal Cancers: A Review
DA Mitrea, EM Froicu, H Prenen… - Critical Reviews in …, 2024 - Elsevier
Introduction and purpose With a significant global impact, treatment of gastrointestinal (GI)
cancers still presents with challenges, despite current multimodality approaches in …
cancers still presents with challenges, despite current multimodality approaches in …
[PDF][PDF] Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signaling in vitro
M Meng, J Tan, H Chen, Z Shi, HY Kwan, T Su - Heliyon, 2023 - cell.com
Colorectal cancer (CRC) is the third most common cause of cancer-related morbidity
worldwide, with an estimated of 1.85 million new cases and 850,000 deaths every year …
worldwide, with an estimated of 1.85 million new cases and 850,000 deaths every year …
[HTML][HTML] Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance
H Abushukair, O Ababneh, S Zaitoun… - Cancer Treatment and …, 2022 - Elsevier
Immune checkpoint inhibitors (ICIs) have significantly advanced colorectal cancer treatment
in recent years. Antibodies that target the proteins programmed cell death-1 (PD-1) …
in recent years. Antibodies that target the proteins programmed cell death-1 (PD-1) …
[HTML][HTML] Objective response after immune checkpoint inhibitors in a chemotherapy-refractory pMMR/MSS metastatic rectal cancer patient primed with experimental …
A Hirschfeld, D Gurell, M Har-Noy - Translational Medicine …, 2024 - Springer
Abstract Background Immune Checkpoint Inhibitor (ICI) immunotherapy is most effective in
immune effector cell infiltrated 'hot'tumor lesions, such as occurs in deficient mismatch …
immune effector cell infiltrated 'hot'tumor lesions, such as occurs in deficient mismatch …